Department of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Department of Urology, Leuven University Hospitals, Leuven, Belgium.
Int J Urol. 2021 Apr;28(4):390-395. doi: 10.1111/iju.14471. Epub 2021 Jan 6.
To investigate whether the new prostate cancer grade groups model provides significant predictive value and better patient stratification on tumor progression after radical prostatectomy compared with the former Gleason grading models.
Men treated at a tertiary center by radical prostatectomy between 2005 and 2017 were analyzed. The outcomes of interest were clinical progression-free and cancer-specific survival. Multivariate Cox regression analysis, C-index and decision curve analysis were carried out using three-tier (Gleason score 6, 7 and 8-10), four-tier (Gleason score 6, 7, 8 and 9-10) and new grade groups model.
In total, 1759 men were included in the analysis. At a median of 87 months (interquartile range 51-134 months) of follow up, clinical progression was detected in 78 (4.4%) and cancer-related death in 42 (2.4%) patients. The hazard ratio of clinical progression-free was 2.3, 5.7, 5.2 and 29.5; the hazard ratio of cancer-specific survival was 1.7, 3.2, 4.8 and 11.8 in the grade groups 2-5, relative to grade group 1, respectively. The grade groups model had higher C-index in comparison with four- and three-tier grading models for clinical progression-free survival 0.88 versus 0.85 versus 0.83 and for cancer-specific survival 0.82 versus 0.80 versus 0.80, respectively. In the decision curve analysis, the grade groups model shows marginally better net benefit on clinical progression-free and cancer-specific survival.
The new model shows better performance in comparison with former Gleason grading models on the prediction of long-term oncological outcomes.
研究新的前列腺癌分级模型与前 Gleason 分级模型相比,在根治性前列腺切除术后肿瘤进展方面是否提供了显著的预测价值和更好的患者分层。
分析 2005 年至 2017 年在一家三级中心接受根治性前列腺切除术的男性患者。主要研究终点为临床无进展和癌症特异性生存。采用多变量 Cox 回归分析、C 指数和决策曲线分析,比较了三分级(Gleason 评分 6、7 和 8-10)、四分级(Gleason 评分 6、7、8 和 9-10)和新分级模型。
共纳入 1759 名患者。中位随访 87 个月(51-134 个月),78 例(4.4%)患者出现临床进展,42 例(2.4%)患者发生癌症相关死亡。临床无进展的危险比为 2.3、5.7、5.2 和 29.5;癌症特异性生存的危险比分别为 1.7、3.2、4.8 和 11.8,对应分级组 2-5 相对于分级组 1。与四分级和三分级模型相比,分级组模型在预测临床无进展生存方面具有更高的 C 指数,分别为 0.88、0.85 和 0.83,癌症特异性生存方面为 0.82、0.80 和 0.80。在决策曲线分析中,分级组模型在预测临床无进展和癌症特异性生存方面显示出略优的净获益。
与前 Gleason 分级模型相比,新模型在预测长期肿瘤学结果方面表现更好。